Korean Circ J.  1992 Feb;22(1):140-145. 10.4070/kcj.1992.22.1.140.

Short-Term Hypolipidemic Effects of Pravastatin in Patients with Hyperlipidemia

• Bae JH
• Kang HS
• Kim KS
• Kim MS
• Song JS

• KMID: 2093364
• DOI: http://doi.org/10.4070/kcj.1992.22.1.140

Abstract

BACKGROUND
Hyperlipidemia is the one of the major risk factors causing the atherosclerosis of coronary arteries. Treatment of hyperlipidemia with drugs has been confirmed the effects of therapy showing a decreased incidence of coronary artery disease. Pravastatin is one of the new HMG-CoA reductase inhibitors and we studied the short-term hypolipidemic effects and safety of pravastatin in patients with hyperlipidemia.
METHODS
We studied 31 patients(7 males and 24 females ; range of age, 36-67 years) for 12 weeks whose plasma levels of total cholesterol were higher than 250mg% after one month period of diet therapy. Pravastatin was administered 10mg/day and measured lipid profiles at 4 week interval.
RESULTS
Pravastatin reduced the plasma total cholesterol from 286.2mg% to 212.3mg% (25.9%), the LDL-cholesterol from 204.2mg% to 143.6mg% (29.7%), the triglyceride from 226.0mg% to 161.4mg% (28.6%) after 12 weeks treatment. The HDL-cholesterol increased from 25.8mg% to 46.4mg% (20.5%) after pravastatin therapy. These changes were disclosed all statistically significant compared to baseline levels(p<0.01). The clinical and laboratory examinations before and after pravastatin treatment showed no particular abnormal findings.
CONCLUSIONS
These results suggested that short-term pravastatin therapy in patients with hyperlipidemia seems to be very effective and safe.

Keyword

Pravastatin; Hyperlipidemia

MeSH Terms

Atherosclerosis
Cholesterol
Coronary Artery Disease
Coronary Vessels
Diet Therapy
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias*
Incidence
Male
Plasma
Pravastatin*
Risk Factors
Triglycerides
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin